89 related articles for article (PubMed ID: 11383676)
1. Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients.
Bonfigli AR; Pieri C; Manfrini S; Testa I; Sirolla C; Ricciotti R; Marra M; Compagnucci P; Testa R
Diabetes Nutr Metab; 2001 Apr; 14(2):71-7. PubMed ID: 11383676
[TBL] [Abstract][Full Text] [Related]
2. A study on the action of vitamin E supplementation on plasminogen activator inhibitor type 1 and platelet nitric oxide production in type 2 diabetic patients.
Vignini A; Nanetti L; Moroni C; Testa R; Sirolla C; Marra M; Manfrini S; Fumelli D; Marcheselli F; Mazzanti L; Rabini RA
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):15-22. PubMed ID: 17949955
[TBL] [Abstract][Full Text] [Related]
3. Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients.
Testa R; Bonfigli AR; Sirolla C; Boemi M; Manfrini S; Mari D; Testa I; Sacchi E; Franceschi C
Diabetes Nutr Metab; 2004 Aug; 17(4):217-21. PubMed ID: 15575342
[TBL] [Abstract][Full Text] [Related]
4. A strong inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients.
Testa R; Bonfigli AR; Sirolla C; Pieri C; Marra M; Antonicelli R; Manfrini S; Compagnucci P; Testa I
Diabetes Nutr Metab; 1999 Dec; 12(6):400-6. PubMed ID: 10782561
[TBL] [Abstract][Full Text] [Related]
5. Vitamin E improves fibrinolytic activity in patients with coronary spastic angina.
Miyamoto S; Kawano H; Takazoe K; Soejima H; Sakamoto T; Hokamaki J; Yoshimura M; Nakamura H; Yodoi J; Ogawa H
Thromb Res; 2004; 113(6):345-51. PubMed ID: 15226088
[TBL] [Abstract][Full Text] [Related]
6. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
[TBL] [Abstract][Full Text] [Related]
7. Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: a double blind, placebo controlled pilot study.
Tam LS; Li EK; Leung VY; Griffith JF; Benzie IF; Lim PL; Whitney B; Lee VW; Lee KK; Thomas GN; Tomlinson B
J Rheumatol; 2005 Feb; 32(2):275-82. PubMed ID: 15693087
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy.
Brazionis L; Rowley K; Jenkins A; Itsiopoulos C; O'Dea K
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):786-91. PubMed ID: 18239151
[TBL] [Abstract][Full Text] [Related]
11. Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers.
Carroll MF; Schade DS
Circulation; 2003 Jul; 108(1):24-31. PubMed ID: 12821556
[TBL] [Abstract][Full Text] [Related]
12. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.
Festa A; Williams K; Tracy RP; Wagenknecht LE; Haffner SM
Circulation; 2006 Apr; 113(14):1753-9. PubMed ID: 16585388
[TBL] [Abstract][Full Text] [Related]
13. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.
Herlihy OM; Barrow BA; Grant PJ; Levy JC
Diabetologia; 2002 May; 45(5):635-41. PubMed ID: 12107743
[TBL] [Abstract][Full Text] [Related]
14. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic dysfunction after gestation is associated to components of insulin resistance and early type 2 diabetes in latino women with previous gestational diabetes.
Morimitsu LK; Fusaro AS; Sanchez VH; Hagemann CC; Bertini AM; Dib SA
Diabetes Res Clin Pract; 2007 Dec; 78(3):340-8. PubMed ID: 17544539
[TBL] [Abstract][Full Text] [Related]
16. Plasma lipid peroxidation and antioxidiant nutrients in type 2 diabetic patients.
Peerapatdit T; Patchanans N; Likidlilid A; Poldee S; Sriratanasathavorn C
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S147-55. PubMed ID: 17718256
[TBL] [Abstract][Full Text] [Related]
17. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
18. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
19. Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy.
Sartori MT; Rigotti P; Marchini F; Spiezia L; Baldan N; Furian L; Varvarikis C; Girolami A
Transplantation; 2003 Apr; 75(7):994-8. PubMed ID: 12698086
[TBL] [Abstract][Full Text] [Related]
20. Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort.
Alessi MC; Nicaud V; Scroyen I; Lange C; Saut N; Fumeron F; Marre M; Lantieri O; Fontaine-Bisson B; Juhan-Vague I; Balkau B; Tregouet DA; Morange PE;
Thromb Haemost; 2011 Sep; 106(3):416-22. PubMed ID: 21800006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
